Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing

Brain

Volumn 120, Issue 12, 1997, Pages 2197-2206

  Moeller, J R ^a   Eidelberg, D ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Ageing; Glucose metabolism; Parkinson's disease; PET

Indexed keywords

FLUORODEOXYGLUCOSE; GLUCOSE;

ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGING; ANALYSIS OF VARIANCE; BRAIN; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; REFERENCE VALUES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031469040     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.12.2197     Document Type: Article

References (45)

1. Agid Y, Blin J, Bonnet AM, Dubois B, Javoy-Agid F, Ruberg M, et al. Does aging contribute to aggravation of Parkinson's disease? In: Calne DB, Crippa D, Comi G, Horowski R, Trabucchi M, editors. Parkinsonism and aging. New York: Raven Press, 1989: 115-23.
2. Alexander GE, Moeller JR. Application of the scaled subprofile model to functional imaging in neuropsychiatriC disorders: a principal component approach to modeling brain function in disease. Hum Brain Mapp 1994; 2: 79-94.
3. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-55.
4. Calne DB. Is idiopathic parkinsonism the consequence of an event or a process? [Review]. Neurology 1994; 44: 5-10.
5. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. [Review]. Mov Disord 1990; 5: 100-8.
6. 18F]fluorodeoxyglucose/PET data. J Nucl Med 1989; 30: 1483-8.
7. 18F-fluorodopa positron emission tomographic studies. Mov Disord 1990; 5: 203-13.
8. 18F-dopa uptake: Absence of an aging effect [see comments]. J Cereb Blood Flow Metab 1993; 13: 881-8. Comment in: J Cereb Blood Flow Metab 1994; 14: 882-3.
9. 18F-dopa uptake: Absence of an aging effect [see comments]. J Cereb Blood Flow Metab 1993; 13: 881-8. Comment in: J Cereb Blood Flow Metab 1994; 14: 882-3.
10. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994; 14: 783-801.
11. 18F-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1995a; 36: 378-83.
12. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995b; 45: 1995-2004.
13. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Przedborski S, et al. The metabolic topography of idiopathic torsion dystonia. Brain 1995c; 118: 1473-84.
14. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Silbersweig D, et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Ann Neurol 1996; 39: 450-9.
15. Evarts EV, Teravainen H, Calne DB. Reaction time in Parkinson's disease. Brain 1981; 104: 167-86.
16. Fahn S, Elton RL, and the UPDRS Development Committee. Unified Parkinson disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease, Vol. 2. Florham Park (NJ): Macmillan, 1987: 293-304.
17. Feamley JM, Lees AJ, Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
18. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-42.
19. Ishikawa T, Dhawan V, Chaly T, Margouleff C, Robeson W, Dahl JR, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. J Nucl Med 1996a; 37: 216-22.
20. 18F]FDOPA/PET. J Nucl Med 1996b; 37: 1760-5.
21. Kearfott KJ, Rottenberg DA, Knowles RJR. A new headholder for PET, CT, and NMR imaging. J Comput Assist Tomogr 1984; 8: 1217-20.
22. Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann Neurol 1995; 38: 260-4.
23. Koller WC. When does Parkinson's disease begin? [Review]. Neurology 1992; 42 (4 Suppl 4): 27-31.
24. Langston JW. Predicting Parkinson's disease. [Review]. Neurology 1990; 40 (10 Suppl 3): 70-4.
25. Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994: 117: 501-7.
26. Moeller JR, Strother SC. A regional covariance approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 1991; 11: A121-35.
27. Moeller JR, Strother SC, Sidtis JJ, Rottenberg DA. Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 1987; 7: 649-58.
28. Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab 1996; 16: 385-98.
29. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119: 585-91.
30. Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Sokoloff L, Kopin IJ,. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci 1990; 10: 860-9.
31. 18F)] 2-fluoro-2-deoxy-D-glucose. Validation of method. Ann Neurol 1979; 6: 371-88.
32. Robeson W, Dhawan V, Takikawa S, Takikawa S, Zanzi I, Margouleff D et al. SuperPETT 3000 Time-of-flight PET tomograph: optimization of factors affecting quantitation. IEEE Trans Nucl Sci 1993; 40: 135-42.
33. 18F]fluorodeoxyglucose positron emission tomographic region-of-interest data. J Cereb Blood Flow Metab 1991; 11: A83-8.
34. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS, Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990; 28: 799-804.
35. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989; 26: 551-7.
36. Schulzer M, Lee CS, Mak EK, Vingerhoets FJG, Calne DB. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994; 117: 509-16.
37. Spetsieris P, Dhawan V, Takikawa S, Margouleff D, Eidelberg D, et al. Imaging cerebral function. IEEE Comput Graphics 1993; 13: 15-26.
38. Takikawa S, Dhawan V, Spetsieris P, Robeson W, Chaly T, Dahl R, et al. Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. Radiology 1993; 188: 131-6.
39. 18F]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994; 35: 955-63.
40. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme, 1988.
41. Teravainen H, Calne DB. Motor system in normal aging and Parkinson's disease. In: Katzman R, Terry R, editors. The neurology of aging. Philadelphia: F. A. Davis, 1983: 85-109.
42. Van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with Iodine-123-β CITSPECT. J Nucl Med 1995; 36: 1175-81.
43. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M. Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994; 36: 759-64.
44. Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994; 36: 237-9.
45. Wolters EC, Calne DB. Is Parkinson's disease related to aging? In: Calne DB, Crippa D, Comi G, Horowski R, Trabucchi M, editors. Parkinsonism and aging. New York: Raven Press, 1989: 125-32.